Evidence map›Paper›PMID 41853813›Full record

ArticleNeuro-oncology advances

Durable disease control in a radiation-induced high-grade glioma harboring

Mohamed Sherief, Maria Fatteh, Jaime Wehr, Matthias Holdhoff, Charles G Eberhart, Valsamo Anagnostou, Karisa C Schreck

Abstract read
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mohamed SheriefDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore.ORCID https://orcid.org/0009-0007-6162-1053
Maria FattehDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore.
Jaime WehrDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore.
Matthias HoldhoffDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore.ORCID https://orcid.org/0000-0002-3285-3484
Charles G EberhartDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore.ORCID https://orcid.org/0000-0002-2910-9427
Valsamo AnagnostouDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore.ORCID https://orcid.org/0000-0001-9480-3047
Karisa C SchreckDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore.ORCID https://orcid.org/0000-0001-7181-3269

Funding

Adult Brain Tumor Consortium (ABTC)UM1CA137443 · NCI · JOHNS HOPKINS UNIVERSITY · PI GROSSMAN, STUART A · 2014 to 2020
$9.7M
Matching genotypes with personalized therapies: Development of a decision support infrastructure to augment the value of precision medicineU01CA274631 · NCI · JOHNS HOPKINS UNIVERSITY · PI ANAGNOSTOU, VALSAMO, BOTSIS, TAXIARCHIS · 2023 to 2025
$1.2M
NCI NIH HHS U01 CA274631NCI NIH HHS UM1 CA137443
6 · The paper itself

Abstract

Radiation-induced gliomas (RIGs) are rare and aggressive secondary brain tumors arising years after cranial irradiation. Their management remains challenging due to prior radiation exposure, which limits additional radiation, and a lack of effective chemotherapies. Recent studies have revealed distinct molecular profiles in RIGs with unclear clinical implications. This study presents the case of an individual who developed a high-grade glioma three decades after curative craniospinal radiation for medulloblastoma. He was treated with repeat radiation and temozolomide chemotherapy but developed recurrence with disseminated leptomeningeal disease thereafter. Molecular profiling of the tumor revealed a loss-of-function

Indexed as

MAPK targeted therapyMEK inhibitorNF1radiation induced gliomaSHP2

Identifiers

PMID41853813
PMCPMC12994696

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.